SEC Comment Letter for IONIS PHARMACEUTICALS INC (IONS) (CIK 0000874015) (IONS) — Jan 26, 2021
IONIS PHARMACEUTICALS INC (IONS) (CIK 0000874015)
Date: Jan. 26, 2021 · CIK: 0000874015 · Accession: 0000000000-21-000948
AI Filing Summary & Sentiment
File numbers found in text: 000-19125
Letter
United States securities and exchange commission logo January 26, 2021 Elizabeth Hougen Chief Financial Officer Ionis Pharmaceuticals, Inc. 2855 Gazelle Court Carlsbad, California Re:Ionis Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2019 Filed March 2, 2020 File No. 000-19125 Dear Ms. Hougen: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
January 26, 2021
Elizabeth Hougen
Chief Financial Officer
Ionis Pharmaceuticals, Inc.
2855 Gazelle Court
Carlsbad, California
Re:Ionis Pharmaceuticals, Inc.
Form 10-K for the Fiscal Year Ended December 31, 2019
Filed March 2, 2020
File No. 000-19125
Dear Ms. Hougen:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences